CST6: A Potential Drug Target and Biomarker for Cysteine 鈥嬧?婸roteinase Inhibition

Target Name: CST6

NCBI ID: G1474

CST6

CST6: A Potential Drug Target and Biomarker for Cysteine 鈥嬧?婸roteinase Inhibition

Introduction

Cysteine 鈥嬧?媝roteinase (Cysteine 鈥嬧?婸rotease Inhibitor, CPI) is a protein that plays a crucial role in maintaining cellular homeostasis, specifically in the regulation of protein levels and degradation. CPI is composed of two distinct subunits, CPI-1 and CPI-2, which are located in the cytoplasm and the endoplasmic reticulum, respectively. These subunits contain unique catalytic domains that give them unique structural features and functions. In this article, we will discuss CST6, a cysteine 鈥嬧?媝roteinase inhibitor that has been identified as a potential drug target and biomarker for cysteine 鈥嬧?媝roteinase inhibition.

The Structure and Functions of CPI

CPI is a 21-kDa protein that contains two distinct subunits, CPI-1 and CPI-2. Both subunits share a conserved catalytic core, which consists of a nucleotide-binding oligomerization domain (NBO), a Rossmann-fold, and a carboxylic acid loop. However, they differ in their lengths and their specific functions.

CPI-1 is the longer subunit and contains a unique NBO that is specific for cysteine 鈥嬧?媝roteinase. This NBO is responsible for coordinating the catalytic activity of CPI-1 and for protecting the substrate from irreversible inhibition by other cysteine 鈥嬧?媝rotease. Additionally, CPI-1 contains a unique Rossmann-fold that is specific for CPI-2. This folds are involved in the substrate recognition and the catalytic activity of CPI-2.

CPI-2 is the shorter subunit and contains a unique NBO that is specific for CPI-1. This NBO is responsible for coordinating the catalytic activity of CPI-2 and for protecting the substrate from irreversible inhibition by other cysteine 鈥嬧?媝roteinases (8 ).

The Functions of CPI

CPI is involved in the regulation of protein levels and degradation by cysteine 鈥嬧?媝roteinases. These enzymes are responsible for breaking down a variety of proteins, including proteins involved in cell signaling, DNA repair, and inflammation. The activity of CPI is regulated by multiple factors, including the concentration of cysteine 鈥嬧?媝roteinase, the concentration of its substrates, and the presence of inhibitors.

CPI has been shown to have a variety of cellular functions. For example, it has been shown to regulate the levels of cytoskeletal proteins, such as microtubules and actin. Additionally, CPI has been shown to play a role in the regulation of cell cycle progression, and it has been shown to interact with the transcription factor, p53.

CPI has also been shown to have a variety of potential therapeutic applications. For example, it has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, CPI has been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

The Potential of CST6 as a Drug Target

The identification of CPI as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases. CPI has been shown to play a role in the regulation of cellular homeostasis, and it is involved in the regulation of protein levels and degradation. Additionally, CPI has been shown to have a variety of cellular functions, including the regulation of

Protein Name: Cystatin E/M

Functions: High affinity inhibitor for cathepsin L, cathepsin L2 (cathepsin V), and legumain (PubMed:30425301). Involved in the regulation of epidermal cornification, and hair follicle morphogenesis and maintenance (PubMed:30425301)

The "CST6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CST6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets